India · Delayed Price · Currency is INR Laxmi Organic Industries Earnings Call Transcripts
Fiscal Year 2026
-
Q3 saw revenue and EBITDA decline year-over-year due to price moderation and product phase-outs, but ethyl acetate spreads and key feedstock prices have begun to recover. New capacities at Dahej and Lote are on track, with specialty and fluorination segments expected to ramp up in FY2027.
-
Q2 revenue declined 9% year-over-year, mainly due to a 20% drop in specialty from product phase-out, price moderation, and deferred orders. Gross margin improved to 33.1%, but EBITDA margin fell to 5.3%. New capacities and contracts are expected to drive recovery in H2 and FY2027.
-
Q1 FY26 saw a 4% revenue decline despite 8% volume growth, with Essentials up 4% and Specialities down 18% due to a product phase-out and deferred deliveries. Major CapEx projects remain on track, and supply chain digitization is underway to drive efficiency.
Fiscal Year 2025
-
Achieved 11% volume growth and improved gross margin despite soft market conditions. Specialty EBITDA margin held at 23%, essentials at 3%, with new projects and product diversification underway. No equity dilution planned; CapEx and debt remain well managed.
-
Double-digit growth in volumes, revenues, and EBITDA was achieved year-on-year, driven by operational excellence and capacity expansion. Specialty and essential segments both saw strong performance, while major CapEx projects remain on track and margins are expected to stay robust.
-
Double-digit year-over-year growth in revenue and volume was achieved, with strong performance in both essentials and specialties segments. Major capex projects are on track, and the company targets sustained EBITDA and further market expansion despite ongoing weakness in agrochemicals.
-
Q1 FY2025 saw 4% year-on-year revenue growth and 15% higher EBITDA, despite a maintenance shutdown. The company targets doubling revenue and tripling EBITDA by FY2028, supported by a INR 1,100 crore CapEx plan and robust specialty segment growth.